Related Experiment Video
Updated: Sep 4, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
[Therapeutic developments and advances in B-cell lymphoma].
1Department of Hematology and Oncology, Mie University Graduate School of Medicine.
Summary
Rituximab has improved B-cell lymphoma treatment, but 30-40% of diffuse large B-cell lymphoma (DLBCL) patients still face poor outcomes. Novel targeted therapies and immunotherapies offer new hope for refractory cases.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- B-cell lymphomas represent a significant portion of malignant lymphomas, with rituximab-based therapies improving outcomes.
- The standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen is effective for many diffuse large B-cell lymphoma (DLBCL) patients, but a substantial subset experiences treatment failure.
- Molecular research has elucidated lymphoma pathogenesis and identified prognostic factors, driving the development of new therapeutic strategies.
Purpose of the Study:
- To review clinically significant studies on B-cell lymphoma treatment strategies.
- To highlight advancements in managing diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and lymphoplasmacytic lymphoma.
- To discuss novel therapeutic agents and immunotherapies for refractory or relapsed B-cell lymphomas.
Main Methods:
- Review of impactful clinical studies on B-cell lymphoma treatment.
- Analysis of data on novel targeted agents and immunotherapies.
- Discussion of therapeutic strategies for DLBCL, follicular lymphoma, and lymphoplasmacytic lymphoma.
Main Results:
- Rituximab has significantly improved treatment outcomes for B-cell lymphomas.
- Despite R-CHOP efficacy, 30-40% of DLBCL patients have unsatisfactory outcomes, necessitating alternative approaches.
- Emerging immunotherapies like CAR T-cell and bispecific antibody therapies represent a paradigm shift for relapsed/refractory DLBCL.
Conclusions:
- Novel targeted agents and immunotherapies are crucial for overcoming treatment resistance in B-cell lymphomas.
- Continued research into molecular mechanisms and therapeutic targets is essential for improving patient survival.
- The discussed treatment strategies offer promising avenues for managing challenging B-cell lymphoma cases.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
01:22Bone Marrow Sampling and Transplants
489
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
489
01:24B Cell Activation and Differentiation
5.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
5.2K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K